Tocilizumab with or without flupentixol-melitracen for thyroid eye disease
Tests adding flupentixol-melitracen to tocilizumab in adults with thyroid-associated ophthalmopathy.
Key facts
- Who runs it
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 12 Dec 2024
- Planned end
- 12 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)
- Tocilizumab(400mg)
- Record updated
- 16 April 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Aged between 18 and 80 years (inclusive)
- Meets internationally recognized diagnostic criteria for TED with the more severely affected eye in moderate to severe active phase. Meeting any one of the following criteria qualifies as moderate to severe: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm. A Clinical Activity Score (CAS) of ≥3 or a score of 2 combined with MRI evidence indicating active disease is defined as active
- Normal thyroid function within one month prior to enrollment: including those currently taking antithyroid drugs or not requiring medication, with FT3 and FT4 levels within normal range and TSH either normal or decreased
- HAMA (Hamilton Anxiety Rating Scale) score of ≥14
- Voluntary participation and provision of informed consent
Who cannot take part
- Received radioactive iodine treatment or hepatitis vaccination within three months prior to enrollment
- Received systemic immunotherapy for TAO, including oral or intravenous glucocorticoids, other immunosuppressants, or orbital radiotherapy within one month prior to enrollment
- communicable disease
- Severe mental disorders that affect compliance
- Presence of other clinically significant or unstable systemic diseases
- Severe cardiac, hepatic, or renal insufficiency (including myocardial ischemia or myocardial infarction, arrhythmias, and heart failure; ALT, AST ≥ 3 times the upper limit of normal; eGFR < 60 ml/min/1.73 m²)
- Pregnancy or planning to become pregnant
- Currently breastfeeding
- Planning to undergo other treatments during the course of this study
- Patients who are unlikely to complete the entire course of treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity. The activity of TAO is commonly evaluated using the Clinical Activity Score (CAS). Tocilizumab serves as a second-line treatment option for patients with moderate to severe active TAO. Additionally, it is common for TAO patients to experience anxiety, which may exacerbate their condition and negatively impact prognosis. Therefore, we have designed this randomized controlled study to evaluate the impact of Flupentixol Melitracen (Lepan) on the treatment outcomes of participants receiving Tocilizumab (Actemra).
The 2 groups in the trial
- Tocilizumab combined with Flupentixol MelitracenTreatment being tested
Treatment: Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)
- TocilizumabExisting treatment, for comparison
Treatment: Tocilizumab(400mg)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy: A Prospective Exploratory Study
- Plain-language title
- Tocilizumab with or without flupentixol-melitracen for thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
- Fit questions
- Built from NCT06927375, who can take part
- Record updated
- 16 April 2025